FUROSCIX ReadyFlow Autoinjector

About MannKind

MannKind Corporation has evolved from a development-stage entity into a commercial organization with a diversified portfolio anchored by its proprietary Technosphere® inhalation platform. The company's strategy combines the commercialization of its own products—Afrezza® (inhaled insulin) and V-Go®—with strategic partnerships, as evidenced by the success of Tyvaso DPI®, and targeted acquisitions like scPharmaceuticals (FUROSCIX®). With a focus on cardiometabolic and orphan lung diseases, MannKind aims to drive growth through label expansions, pediatric studies, and leveraging its validated platform for new therapeutic applications.

Therapeutic Areas